{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/attention-deficit-hyperactivity-disorder/prescribing-information/amfetamines/","result":{"pageContext":{"chapter":{"id":"cdfd970d-3454-539a-8119-612214e9ba0c","slug":"amfetamines","fullItemName":"Amfetamines","depth":2,"htmlHeader":"<!-- begin field da9e2dbb-9903-42db-a2c7-b9cc1b07e276 --><h2>Amfetamines</h2><!-- end field da9e2dbb-9903-42db-a2c7-b9cc1b07e276 -->","summary":"","htmlStringContent":"<!-- begin item d8c10d47-7059-45ea-acaa-72f9390a9200 --><!-- begin field 595ae22a-cbc4-42ea-a7a3-24dfb918fae7 --><ul><li>Dexamfetamine and lisdexamfetamine are <em>always </em>initiated in secondary care by a specialist. However, treatment may be continued and <a class=\"topic-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/management/management/#managing-confirmed-adhd\">monitored</a> by a general practitioner under a shared-care protocol.</li></ul><!-- end field 595ae22a-cbc4-42ea-a7a3-24dfb918fae7 --><!-- end item d8c10d47-7059-45ea-acaa-72f9390a9200 -->","topic":{"id":"58fdf356-8ba5-546f-8dc0-2f52caf10b0d","topicId":"634d93f6-99ac-40ea-821e-2886075c4f40","topicName":"Attention deficit hyperactivity disorder","slug":"attention-deficit-hyperactivity-disorder","lastRevised":"Last revised in January 2021","chapters":[{"id":"97f99690-0b45-5db9-91f6-a4ccf1441f55","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3288c19f-08ea-5db5-9fe3-2a19e4e9480e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"117c3288-2c4b-54a9-93a6-e73cfa827ea6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"05022ed2-5af8-5139-9aee-325340958ba7","slug":"changes","fullItemName":"Changes"},{"id":"280f9139-8e61-5232-b633-87792a692c21","slug":"update","fullItemName":"Update"}]},{"id":"7df3faa3-c76c-5513-8300-b8e6c29a6710","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"dd6487fd-840a-583c-9def-1b3fbf119433","slug":"goals","fullItemName":"Goals"},{"id":"7d672b8e-e109-5eee-9f6a-937dc8647595","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6ee4b93a-2830-5f51-9991-1c95ef010724","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f40bd230-c678-561c-9d40-5bc8424b3e61","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"473473fc-1cf7-5675-876d-9cf4806ca71c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b7ed8daa-37ed-5957-8040-2744764b2b9c","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9199d39e-4690-591d-9e22-737af0484d8b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"60a29f8c-bc0e-5bb1-9846-a4ef0725acfb","slug":"definition","fullItemName":"Definition"},{"id":"0e5e3505-ad73-5fe3-889b-d803507818a4","slug":"causes","fullItemName":"Causes"},{"id":"f3cd314a-8d03-53ce-a0c0-924d345fc73e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b286aedf-f99c-5903-9289-953caa385920","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ab5906d5-d2b3-5bc3-bfcf-512c0aa8be1e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d3399591-ed2d-5c77-9855-2e0b917c37ae","slug":"when-to-suspect-adhd","fullItemName":"When to suspect ADHD"},{"id":"79f2001b-57c3-521d-a4b3-a30df47980b7","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"2bfc757a-5a5f-5796-bd7d-b0b48edaa5fc","fullItemName":"Management","slug":"management","subChapters":[{"id":"0042040f-0d1c-5531-856f-e59d3ecbfe9f","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c3622cf7-82a4-5194-ba3d-ee79d5dcc6b1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e54ebc77-0347-59b3-9363-2fa71e52a56d","slug":"methylphenidate","fullItemName":"Methylphenidate"},{"id":"4cb27755-8a20-55e7-abf6-188f7ef4cc15","slug":"atomoxetine","fullItemName":"Atomoxetine"},{"id":"cdfd970d-3454-539a-8119-612214e9ba0c","slug":"amfetamines","fullItemName":"Amfetamines"}]},{"id":"c30641a4-ca7b-5cc3-bd1a-68cb35616b7b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"114d2691-2ead-5200-a465-7a97d6ea302e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"42cd6093-4642-503a-aee2-abe24e0af20c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"ebdae4e0-6a27-5f95-af59-4d19d02719c5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2dc4be40-cd79-5b84-940c-7d3b5ddf196d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b89b6177-f75f-51ac-b701-99a0ce4f254e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5c21ec37-f21e-535e-81a7-d99081cf961e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cdb8e542-54f7-55a2-9ef4-42e064fccfff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c3622cf7-82a4-5194-ba3d-ee79d5dcc6b1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b328a48e-7fc6-5d4a-a02c-6fa53812299b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field bbcf7dc4-6ed9-47a9-8ed7-d375e6b46db4 --><h3>What adverse effects are associated with dexamfetamine and lisdexamfetamine?</h3><!-- end field bbcf7dc4-6ed9-47a9-8ed7-d375e6b46db4 -->","summary":"","htmlStringContent":"<!-- begin item 37df5382-26d4-4512-ab9c-826a685ef1d6 --><!-- begin field a94ef2b2-6be5-498b-b6e1-340b02afaaed --><ul><li><strong>Adverse effects of amfetamines include:</strong><ul><li><strong>Metabolic effects</strong> such as decreased appetite with moderately reduced weight and growth during prolonged use.</li><li><strong>Psychiatric effects </strong>such as insomnia, anxiety, aggression, agitation, lability, mood swings, and depression. </li><li><strong>Central nervous system effects</strong> such as dizziness, dyskinesia, tremor, psychomotor hyperactivity, confusion, irritability, and headache.</li><li><strong>Cardiovascular system effects</strong> such as hypertension, tachycardia, QTc interval prolongation, cardiomyopathy, and myocardial infarction.</li><li><strong>Gastrointestinal effects</strong> such as diarrhoea, constipation, abdominal cramps, nausea, and vomiting.</li><li><strong>Urogenital effects </strong>such as sexual dysfunction.</li><li><strong>Ophthalmological effects</strong> such as mydriasis. Very rarely, angle-closure glaucoma may occur.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2020b</a>]</p><!-- end field a94ef2b2-6be5-498b-b6e1-340b02afaaed --><!-- end item 37df5382-26d4-4512-ab9c-826a685ef1d6 -->","subChapters":[]},{"id":"cbabe3eb-70ae-5a9c-93fc-abd824cc69a9","slug":"interactions","fullItemName":"Interactions","depth":3,"htmlHeader":"<!-- begin field 898606d3-517f-4a03-8d7f-b4753d9839a1 --><h3>What key interactions are associated with amfetamines (dexamfetamine and lisdexamfetamine)?</h3><!-- end field 898606d3-517f-4a03-8d7f-b4753d9839a1 -->","summary":"","htmlStringContent":"<!-- begin item 93cb118a-fcac-493a-9008-56cac57137a9 --><!-- begin field a448a1bd-d5c5-4594-8472-731fc791443b --><p><strong>Key drug interactions with amfetamines include:</strong></p><ul><li><strong>Moclobemide </strong>— may potentially cause fatal hypertensive crisis and concurrent use with an amfetamine should be avoided.</li><li><strong>Monoamine oxidase inhibitors (MAOIs) </strong>— concurrent use of two or more serotonergic drugs may increase the risk of serotonin syndrome and symptoms similar to neuroleptic malignant syndrome, therefore, do not prescribe an MAOI to a person taking an amfetamine. Be aware that an amfetamine should not be used for at least 14 days after stopping treatment with an MAOI, and treatment with an MAOI should not be initiated within 14 days after stopping an amfetamine.</li><li><strong>Rasagiline </strong>— increases the risk of hypertensive crisis and concurrent use with an amfetamine should be avoided.</li><li><strong>Atomoxetine </strong>— concurrent use with amfetamines increases the risk of psychosis and movement disorders. If concurrent use is indicated, be aware of this risk and consider reducing or stopping the drug if any symptoms of psychosis or movement disorders occur.</li><li><strong>Haloperidol </strong>— concurrent use with amfetamines may inhibit the stimulant effect of the amfetamine and therefore dexamfetamine and lisdexamfetamine may be less effective in people taking haloperidol.</li><li><strong>Tricyclic antidepressants </strong>— concurrent use with amfetamines increases cardiovascular risk and should be avoided.</li><li><strong>Selective serotonin reuptake inhibitors (SSRIs) or </strong><strong>noradrenaline reuptake inhibitors (SNRIs</strong>) — concurrent use with amfetamines increases the risk of serotonin syndrome and neurotoxic reaction. The significance of this interaction is unclear but awareness of this interaction is advised.</li><li><strong>HIV-protease inhibitors </strong>— concurrent use with amfetamines increases the concentration of amfetamines and is potentially fatal. Avoidance or dose reduction is advised.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/attention-deficit-hyperactivity-disorder/references/\">BNF 75, 2018</a>]</p><!-- end field a448a1bd-d5c5-4594-8472-731fc791443b --><!-- end item 93cb118a-fcac-493a-9008-56cac57137a9 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}